Bioequivalence for topical products-An update

Pharmaceutical Research

Volumn 27, Issue 12, 2010, Pages 2590-2601

  Narkar, Yogeeta ^a  

^a Product Development   (United States)

Author keywords

Bioequivalence; Dermatopharmacokinetics; In vitro diffusion; Microdialysis; Near infra red; Tape stripping; Topical

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; ACETYLSALICYLIC ACID; ALCLOMETASONE DIPROPIONATE; BENZOIC ACID; CAFFEINE; CHLORAMPHENICOL; CORTICOSTEROID; ECONAZOLE; ESTRADIOL; HIPPURIC ACID; KETOPROFEN; LIDOCAINE; MOMETASONE FUROATE; NICOTINAMIDE; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; RETINOIC ACID; SALICYLIC ACID; SALICYLIC ACID METHYL ESTER; TESTOSTERONE; THIOUREA; TOPICAL AGENT; ULOBETASOL PROPIONATE;

AREA UNDER THE CURVE; BIOEQUIVALENCE; CREAM; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG PENETRATION; GEL; HUMAN; IN VITRO STUDY; MAXIMUM PLASMA CONCENTRATION; MICRODIALYSIS; NEAR INFRARED SPECTROSCOPY; NONHUMAN; OINTMENT; PRIORITY JOURNAL; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, TOPICAL; HUMANS; MICRODIALYSIS; SPECTROSCOPY, NEAR-INFRARED; THERAPEUTIC EQUIVALENCY;

EID: 78651270823     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-010-0250-3     Document Type: Review

References (112)

1. OGD. Generic Competition and Drug Prices. http://www.fda.gov/AboutFDA/ CentersOffices/CDER/ucm129385.htm (accessed 6/25/2010).
2. US FDA. Guidance for Industry. Topical dermatologic corticosteroids: In-vivo bioequivalence. Rockville: Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 1995.
3. Wiedersberg S, Leopold CS, Guy RH. Bioavailability and bioequivalence of topical glucocorticoids. Eur J Pharm Biopharm. 2008;68:453-66.
4. Pershing LK, Bakhtian S, Poncelet CE, Corlett JL, Shah VP. Comparison of skin stripping, in vitro release, and skin blanching response methods to measure dose response and similarity of triamcinolone acetonide cream strengths from two manufactured sources. J Pharm Sci. 2002;91:1312-23.
5. Au WL, Skinner M, Kanfer I. Bioequivalence assessment of topical clobetasol propionate products using visual and chromametric assessment of skin blanching. J Pharm Pharm Sci. 2008;11:160-6.
6. Lionberger RA. FDA critical path initiatives: Opportunities for generic drug development. AAPS J. 2008;10:103-9.
7. Muller M, Brunner M, Schmid R, Putz EM, Schmiedberger A, Wallner I, et al. Comparison of three different experimental methods for the assessment of peripheral compartment pharmacokinetics in humans. Life Sci. 1998;62:PL227-34.
8. Volden G, Thorsrud AK, Bjornson I, Jellum E. Biochemical composition of suction blister fluid determined by high resolution multicomponent analysis (capillary gas chromatography-mass spectrometry and two-dimensional electrophoresis). J Invest Dermatol. 1980;75:421-4.
9. Svedman P, Svedman C. Skin mini-erosion sampling technique: Feasibility study with regard to serial glucose measurement. Pharm Res. 1998;15:883-8.
10. Schrolnberger C, Brunner M, Mayer BX, Eichler HG, Muller M. Application of the minimal trauma tissue biopsy to transdermal clinical pharmacokinetic studies. J Control Release. 2001;75:297-306.
11. Treffel P, Makki S, Faivre B, Humbert P, Blanc D, Agache P. Citropten and bergapten suction blister fluid concentrations after solar product application in man. Skin Pharmacol. 1991;4:100-8.
12. Makki S, Treffel P, Humbert P, Agache P. High-performance liquid chromatographic determination of citropten and bergapten in suction blister fluid after solar product application in humans. J Chromatogr. 1991;563:407-13.
13. Surber C, Wilhelm KP, Bermann D, Maibach HI. In vivo skin penetration of acitretin in volunteers using three sampling techniques. Pharm Res. 1993;10:1291-4.
14. Herkenne C, Alberti I, Naik A, Kalia YN, Mathy FX, Preat V, et al. In vivo methods for the assessment of topical drug bioavailability. Pharm Res. 2008;25:87-103.
15. Zhou X, Liu D, Liu H, Yang Q, Yao K, Wang X, et al. Effect of low molecular weight chitosans on drug permeation through mouse skin: 1. Transdermal delivery of baicalin. J Pharm Sci. 2010;99:2991-8.
16. Yuan JS, Yip A, Nguyen N, Chu J, Wen XY, Acosta EJ. Effect of surfactant concentration on transdermal lidocaine delivery with linker microemulsions. Int J Pharm. 2010;392:274-84.
17. Sapra B, Jain S, Tiwary AK. Percutaneous permeation enhancement by terpenes: Mechanistic view. AAPS J. 2008;10:120-32.
18. US FDA. Extended release oral dosage forms: Development, evaluation and application of in vitro/in vivo correlations. Rockville: Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 1997.
19. USP. <1088> In vitro and in vivo evaluation of dosage forms. United States Pharmacopeia 32/National Formulary 27. Rockville: The USP; 2010.
20. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel Dekker; 1982.
21. Shaw JE, Chandrasekaran SK, Michaels AS, Taskovich L. In: Maibach HI, editor. Controlled transdermal delivery, in vitro and in vivo. New York: Churchill-Livingstone; 1975. p. 138-46.
22. Hadgraft J, Beutner D, Michael Wolff H. In vivo-in vitro comparisons in the transdermal delivery of nitroglycerin. Int J Pharm. 1993;89:R1-4.
23. Rohr UD, Altenburger R, Kissel T. Pharmacokinetics of the transdermal reservoir membrane system delivering betaestradiol: In vitro/in vivo-correlation. Pharm Res. 1998;15:877-82.
24. Venkateshwaran S. In vitro-in vivo correlation for transdermal delivery. Coronado: IBC International Conference on Transdermal Drug Delivery; 1997. p. 15-16.
25. Franz TJ, Lehman PA, Raney SG. Use of excised human skin to assess the bioequivalence of topical products. Skin Pharmacol Physiol. 2009;22:276-86.
26. Franz TJ. Percutaneous absorption on the relevance of in vitro data. J Invest Dermatol. 1975;64:190-5.
27. Feldmann RJ, Maibach HI. Absorption of some organic compounds through the skin in man. J Invest Dermatol. 1970;54:399-404.
28. Bronaugh RL, Stewart RF. Methods for in vitro percutaneous absorption studies III: Hydrophobic compounds. J Pharm Sci. 1984;73:1255-8.
29. Scott RC, Ramsey JD. Comparison of the in vivo and in vitro percutaneous absorption of a lipophilic molecule (cypermethrin, a pyrethroid insecticide). J Invest Dermatol. 1987;89:142-6.
30. Ramsey JD, Woollen BH, Auton TR, Scott RC. The predictive accuracy of in vitro measurements for the dermal absorption of a lipophilic penetrant (fluazifop-butyl) through rat and human skin. Fundam Appl Toxicol. 1994;23:230-6.
31. US FDA. Guidance for Industry. Nonsterile semisolid dosage forms, scale-up and postapproval changes: Chemistry, manufacturing, and controls; in vitro release testing and in vivo bioequivalence documentation. Rockville: Food and Drug Administration, Center for Drug Evaluation and Research (CDER); 1997.
32. Shah VP, Flynn GL, Yacobi A, Maibach HI, Bon C, Fleischer NM, et al. Bioequivalence of topical dermatological dosage forms-methods of evaluation of bioequivalence. Pharm Res. 1998;15:167-71.
33. Rougier A, Lotte C, Maibach HI. In vivo percutaneous penetration of some organic compounds related to anatomic site in humans: Predictive assessment by the stripping method. J Pharm Sci. 1987;76:451-4. (Pubitemid 17118283)
34. US FDA. Guidance for industry on special protocol assessment. http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/ Guidances/ucm080571.pdf (accessed 6/ 25/2010).
35. Pershing LK. Bioequivalence assessment of three 0.025% tretinoin gel products: Dermatopharmacokinetic vs. clinical trial methods. http://www.fda.gov/ohrms/dockets/ac/01/slides/ 3804s2-02-Pershing//index.htm (accessed 6/25/2010).
36. Franz TJ. Study # 1, avita gel 0.025% vs retin-a gel 0.025%. http:// www.fda.gov/ohrms/dockets/ac/01/slides/3804s2-03-Franz.pdf (accessed 6/25/2010).
37. Conner DP. Differences in DPK methods. http://www.fda.gov/ ohrms/dockets/ac/01/slides/3804s2-05-conner//index.htm (accessed 6/25/2010).
38. Puglia C, Blasi P, Rizza L, Schoubben A, Bonina F, Rossi C, et al. Lipid nanoparticles for prolonged topical delivery: An in vitro and in vivo investigation. Int J Pharm. 2008;357:295-304.
39. N'Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Improved bioequivalence assessment of topical dermatological drug products using dermatopharmacokinetics. Pharm Res. 2009;26:316-28.
40. Pershing LK. Final report to Food and Drug Administration (FDA): Dermatopharmacokinetic bioequivalence study on three tretinoin gel, 0.025% products. Salt Lake: University of Utah; 2000.
41. Pershing LK, Nelson JL, Corlett JL, Shrivastava SP, Hare DB, Shah VP. Assessment of dermatopharmacokinetic approach in the bioequivalence determination of topical tretinoin gel products. J Am Acad Dermatol. 2003;48:740-51.
42. N'Dri-Stempfer B, Navidi WC, Guy RH, Bunge AL. Optimizing metrics for the assessment of bioequivalence between topical drug products. Pharm Res. 2008;25:1621-30.
43. Navidi W, Hutchinson A, N'Dri-Stempfer B, Bunge A. Determining bioequivalence of topical dermatological drug products by tape-stripping. J Pharmacokinet Pharmacodyn. 2008;35:337-48.
44. Au WL, Skinner M, Kanfer I. Comparison of tape stripping with the human skin blanching assay for the bioequivalence assessment of topical clobetasol propionate formulations. J Pharm Pharm Sci. 2010;13:11-20.
45. Kalia YN, Alberti I, Sekkat N, Curdy C, Naik A, Guy RH. Normalization of stratum corneum barrier function and transepidermal water loss in vivo. Pharm Res. 2000;17:1148-50.
46. Holford NH, Sheiner LB. Understanding the dose-effect relationship: Clinical application of pharmacokineticpharmacodynamic models. Clin Pharmacokinet. 1981;6:429-53.
47. Russell LM, Wiedersberg S, Delgado-Charro MB. The determination of stratum corneum thickness: An alternative approach. Eur J Pharm Biopharm. 2008;69:861-70.
48. Pershing LK, Corlett J, Jorgensen C. In vivo pharmacokinetics and pharmacodynamics of topical ketoconazole and miconazole in human stratum corneum. Antimicrob Agents Chemother. 1994;38:90-5.
49. Alberti I, Kalia YN, Naik A, Bonny JD, Guy RH. In vivo assessment of enhanced topical delivery of terbinafine to human stratum corneum. J Control Release. 2001;71:319-27.
50. Alberti I, Kalia YN, Naik A, Bonny J, Guy RH. Effect of ethanol and isopropyl myristate on the availability of topical terbinafine in human stratum corneum, in vivo. Int J Pharm. 2001;219:11-9.
51. Alberti I, Kalia YN, Naik A, Guy RH. Assessment and prediction of the cutaneous bioavailability of topical terbinafine, in vivo, in man. Pharm Res. 2001;18:1472-5. (Pubitemid 32977255)
52. Clarys P, Gabard B, Lambrecht R, Barel A, Bieli E, Ludi S. There is no influence of a temperature rise on in vivo adsorption of UV filters into the stratum corneum. J Dermatol Sci. 2001;27:77-81.
53. Fernandez C, Nielloud F, Fortune R, Vian L, Marti-Mestres G. Benzophenone-3: Rapid prediction and evaluation using noninvasive methods of in vivo human penetration. J Pharm Biomed Anal. 2002;28:57-63.
54. Wissing SA, Muller RH. Solid lipid nanoparticles as carrier for sunscreens: In vitro release and in vivo skin penetration. J Control Release. 2002;81:225-33.
55. Jacobi U, Weigmann HJ, Baumann M, Reiche AI, Sterry W, Lademann J. Lateral spreading of topically applied UV filter substances investigated by tape stripping. Skin Pharmacol Physiol. 2004;17:17-22.
56. Sarveiya V, Risk S, Benson HA. Liquid chromatographic assay for common sunscreen agents: Application to in vivo assessment of skin penetration and systemic absorption in human volunteers. J Chromatogr B Anal Technol Biomed Life Sci. 2004;803:225-31.
57. Lboutounne H, Chaulet JF, Ploton C, Falson F, Pirot F. Sustained ex vivo skin antiseptic activity of chlorhexidine in poly(epsilon-caprolactone) nanocapsule encapsulated form and as a digluconate. J Control Release. 2002;82:319-34.
58. Ault JM, Riley CM, Meltzer NM, Lunte CE. Dermal microdialysis sampling in vivo. Pharm Res. 1994;11:1631-9.
59. Groth L. Cutaneous microdialysis. Methodology and validation. Acta Derm Venereol Suppl (Stockh). 1996;197:1-61.
60. Cross SE, Anderson C, Roberts MS. Topical penetration of commercial salicylate esters and salts using human isolated skin and clinical microdialysis studies. Br J Clin Pharmacol. 1998;46:29-35.
61. Benfeldt E. In vivo microdialysis for the investigation of drug levels in the dermis and the effect of barrier perturbation on cutaneous drug penetration. Studies in hairless rats and human subjects. Acta Derm Venereol Suppl (Stockh). 1999;206:1-59.
62. Holmgaard R, Nielsen JB, Benfeldt E. Microdialysis sampling for investigations of bioavailability and bioequivalence of topically administered drugs: Current state and future perspectives. Skin Pharmacol Physiol. 2010;23:225-43.
63. Schmidt S, Banks R, Kumar V, Rand KH, Derendorf H. Clinical microdialysis in skin and soft tissues: An update. J Clin Pharmacol. 2008;48:351-64.
64. Benfeldt E, Bashaw ED, Shah VP. In: Walters K, Roberts MS, editors. Assessment of topical bioequivalence using microdialysis and other techniques. New York: Taylor & Francis; 2007. p. 537-48.
65. Chaurasia CS, Muller M, Bashaw ED, Benfeldt E, Bolinder J, Bullock R, et al. AAPS-FDA workshop white paper: Microdialysis principles, application and regulatory perspectives. Pharm Res. 2007;24:1014-25. (Pubitemid 46675390)
66. Fulzele SV, Babu RJ, Ahaghotu E, Singh M. Estimation of proinflammatory biomarkers of skin irritation by dermal microdialysis following exposure with irritant chemicals. Toxicology. 2007;237:77-88.
67. Teichmann A, Otberg N, Jacobi U, Sterry W, Lademann J. Follicular penetration: Development of a method to block the follicles selectively against the penetration of topically applied substances. Skin Pharmacol Physiol. 2006;19:216-23.
68. McCleverty D, Lyons R, Henry B. Microdialysis sampling and the clinical determination of topical dermal bioequivalence. Int J Pharm. 2006;308:1-7.
69. Benfeldt E, Hansen SH, Volund A, Menne T, Shah VP. Bioequivalence of topical formulations in humans: Evaluation by dermal microdialysis sampling and the dermatopharmacokinetic method. J Invest Dermatol. 2007;127:170-8.
70. Carneheim C, Stahle L. Microdialysis of lipophilic compounds: A methodological study. Pharmacol Toxicol. 1991;69:378-80.
71. Ward KW, Medina SJ, Portelli ST, Mahar Doan KM, Spengler MD, Ben MM, et al. Enhancement of in vitro and in vivo microdialysis recovery of SB-265123 using Intralipid and Encapsin as perfusates. Biopharm Drug Dispos. 2003;24:17-25.
72. Sun L, Stenken JA. Improving microdialysis extraction efficiency of lipophilic eicosanoids. J Pharm Biomed Anal. 2003;33:1059-71.
73. Groth L, Garcia OP, Benfeldt E. Microdialysis methodology for sampling in the skin. In: Serup J, Jemec GBE, Grove GL, editors. Handbook of non-invasive methods and the skin. Boca Raton: Taylor & Francis; 2006. p. 443-54.
74. Plock N, Kloft C. Microdialysis-theoretical background and recent implementation in applied life-sciences. Eur J Pharm Sci. 2005;25:1-24.
75. Kellogg Jr DL, Zhao JL, Wu Y. Neuronal nitric oxide synthase control mechanisms in the cutaneous vasculature of humans in vivo. J Physiol. 2008;586:847-57.
76. Tettey-Amlalo RN, Kanfer I, Skinner MF, Benfeldt E, Verbeeck RK. Application of dermal microdialysis for the evaluation of bioequivalence of a ketoprofen topical gel. Eur J Pharm Sci. 2009;36:219-25.
77. Ortiz PG, Hansen SH, Shah VP, Menne T, Benfeldt E. The effect of irritant dermatitis on cutaneous bioavailability of a metronidazole formulation, investigated by microdialysis and dermatopharmacokinetic method. Contact Dermat. 2008;59:23-30.
78. Thong HY, Zhai H, Maibach HI. Percutaneous penetration enhancers: An overview. Skin Pharmacol Physiol. 2007;20:272-82.
79. Trommer H, Neubert RH. Overcoming the stratum corneum: The modulation of skin penetration. A review. Skin Pharmacol Physiol. 2006;19:106-21.
80. Korinth G, Jakasa I, Wellner T, Kezic S, Kruse J, Schaller KH. Percutaneous absorption and metabolism of 2-butoxyethanol in human volunteers: A microdialysis study. Toxicol Lett. 2007;170:97-103.
81. Brunner M, Dehghanyar P, Seigfried B, Martin W, Menke G, Muller M. Favourable dermal penetration of diclofenac after administration to the skin using a novel spray gel formulation. Br J Clin Pharmacol. 2005;60:573-7.
82. Mathy FX, Ntivunwa D, Verbeeck RK, Preat V. Fluconazole distribution in rat dermis following intravenous and topical application: A microdialysis study. J Pharm Sci. 2005;94:770-80.
83. Klimowicz A, Farfal S, Bielecka-Grzela S. Evaluation of skin penetration of topically applied drugs in humans by cutaneous microdialysis: Acyclovir vs. salicylic acid. J Clin Pharm Ther. 2007;32:143-8.
84. Garcia Ortiz P, Hansen SH, Shah VP, Menne T, Benfeldt E. Impact of adult atopic dermatitis on topical drug penetration: Assessment by cutaneous microdialysis and tape stripping. Acta Derm Venereol. 2009;89:33-8.
85. Kezic S. Methods for measuring in-vivo percutaneous absorption in humans. Hum Exp Toxicol. 2008;27:289-95.
86. Zhao J, Lui H, McLean DI, Zeng H. Integrated real-time Raman system for clinical in vivo skin analysis. Skin Res Technol. 2008;14:484-92.
87. Crowther JM, Sieg A, Blenkiron P, Marcott C, Matts PJ, Kaczvinsky JR, et al. Measuring the effects of topical moisturizers on changes in stratum corneum thickness, water gradients and hydration in vivo. Br J Dermatol. 2008;159:567-77.
88. Caussin J, Rozema E, Gooris GS, Wiechers JW, Pavel S, Bouwstra JA. Hydrophilic and lipophilic moisturizers have similar penetration profiles but different effects on SC water distribution in vivo. Exp Dermatol. 2009;18:954-61.
89. Darlenski R, Sassning S, Tsankov N, Fluhr JW. Non-invasive in vivo methods for investigation of the skin barrier physical properties. Eur J Pharm Biopharm. 2009;72:295-303.
90. Caspers PJ, Williams AC, Carter EA, Edwards HG, Barry BW, Bruining HA, et al. Monitoring the penetration enhancer dimethyl sulfoxide in human stratum corneum in vivo by confocal Raman spectroscopy. Pharm Res. 2002;19:1577-80.
91. Wascotte V, Caspers P, de Sterke J, Jadoul M, Guy RH, Preat V. Assessment of the "skin reservoir" of urea by confocal Raman microspectroscopy and reverse iontophoresis in vivo. Pharm Res. 2007;24:1897-901.
92. Pudney PD, Melot M, Caspers PJ, Van Der Pol A, Puppels GJ. An in vivo confocal Raman study of the delivery of trans retinol to the skin. Appl Spectrosc. 2007;61:804-11.
93. Melot M, Pudney PD, Williamson AM, Caspers PJ, Van Der Pol A, Puppels GJ. Studying the effectiveness of penetration enhancers to deliver retinol through the stratum cornum by in vivo confocal Raman spectroscopy. J Control Release. 2009;138:32-9.
94. Pirot F, Kalia YN, Stinchcomb AL, Keating G, Bunge A, Guy RH. Characterization of the permeability barrier of human skin in vivo. Proc Natl Acad Sci USA. 1997;94:1562-7.
95. Stinchcomb AL, Pirot F, Touraille GD, Bunge AL, Guy RH. Chemical uptake into human stratum corneum in vivo from volatile and non-volatile solvents. Pharm Res. 1999;16:1288-93.
96. Reddy MB, Stinchcomb AL, Guy RH, Bunge AL. Determining dermal absorption parameters in vivo from tape strip data. Pharm Res. 2002;19:292-8.
97. Medendorp J, Yedluri J, Hammell DC, Ji T, Lodder RA, Stinchcomb AL. Near-infrared spectrometry for the quantification of dermal absorption of econazole nitrate and 4- cyanophenol. Pharm Res. 2006;23:835-43.
98. Medendorp JP, Paudel KS, Lodder RA, Stinchcomb AL. Near infrared spectrometry for the quantification of human dermal absorption of econazole nitrate and estradiol. Pharm Res. 2007;24:186-93.
99. Egawa M. In vivo simultaneous measurement of urea and water in the human stratum corneum by diffuse-reflectance nearinfrared spectroscopy. Skin Res Technol. 2009;15:195-9.
100. Thilwind RE, 't Hooft G, Uzunbajakava NE. Improved depth resolution in near-infrared diffuse reflectance spectroscopy using obliquely oriented fibers. J Biomed Opt. 2009;14:024026.
101. Bhandari M, Lochner H, Tornetta 3rd P. Effect of continuous versus dichotomous outcome variables on study power when sample sizes of orthopaedic randomized trials are small. Arch Orthop Trauma Surg. 2002;122:96-8.
102. Donner A, Eliasziw M. Statistical implications of the choice between a dichotomous or continuous trait in studies of interobserver agreement. Biometrics 1994;50:550-5.
103. Bunge AL, Guy RH. Dermatopharmacokinetics: Improvement of methodology for assessing bioequivalence of topical products: Presentation to FDA advisory committee for pharmaceutical science, October 2003. FDA 2003. http://www.fda.gov/ohrms/ dockets/ac/03/slides/3996S2-07-Bunge.pdf. (accessed 7/31/ 2010).
104. Russell LM, Guy RH. Measurement and prediction of the rate and extent of drug delivery into and through the skin. Expert Opin Drug Deliv. 2009;6:355-69.
105. Johansson J, Lahti A. Topical non-steroidal anti-inflammatory drugs inhibit non-immunologic immediate contact reactions. Contact Dermat. 1988;19:161-5.
106. Poelman MC, Piot B, Guyon F, Deroni M, Leveque JL. Assessment of topical non-steroidal anti-inflammatory drugs. J Pharm Pharmacol. 1989;41:720-2.
107. Duteil L, Queille C, Poncet M, Ortonne JP, Czernielewski J. Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation. Clin Exp Dermatol. 1990;15:195-9.
108. Chan SY, Li Wan Po A. Quantitative evaluation of druginduced erythema by using a tristimulus colour analyzer: Experimental design and data analysis. Skin Pharmacol. 1993;6:298-312.
109. Treffel P, Gabard B. Feasibility of measuring the bioavailability of topical ibuprofen in commercial formulations using drug content in epidermis and a methyl nicotinate skin inflammation assay. Skin Pharmacol. 1993;6:268-75.
110. Tagami H, Tadaki T, Obata M, Koyama J. Functional assessment of the stratum corneum under the influence of oral aromatic retinoid (etretinate) in guinea-pigs and humans. Comparison with topical retinoic acid treatment. Br J Dermatol. 1992;127:470-5.
111. Fluhr JW, Vienne MP, Lauze C, Dupuy P, Gehring W, Gloor M. Tolerance profile of retinol, retinaldehyde and retinoic acid under maximized and long-term clinical conditions. Dermatology. 1999;199 Suppl 1:57-60.
112. Verschoore M, Poncet M, Czernielewski J, Sorba V, Clucas A. Adapalene 0.1% gel has low skin-irritation potential. J Am Acad Dermatol. 1997;36:S104-9.